Business
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
Phase 1a clinical data for remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected
About this update from Assembly Biosciences, Inc.
[{"type":"text","content":"Phase 1a clinical data for remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication and cccDNA formationAssembly Bio will evaluate partnering options for its core inhibitor portfolio prior to further clinical development of the mechanism for HBV cure The company will prioritize resources on its promising portfolio of antiviral programs with a faster path to clinical proof of concept, including ABI-5366 for high-recurrence genital herpes SOUTH SAN FRANCISCO, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an update of results from the final multiple-dose cohort in the ongoing Phase 1a study of its investigational next-generation, highly potent hepatitis B virus (HBV) core inhibitor, ABI-4334 (4334), and announced it will evaluate partnering opportunities for its core inhibitor portfolio and prioritize its expanded virology pipeline. “We are encouraged by the promising clinical profile of our most potent core inhibitor candidate, 4334, and its potential to reach the clinical exposures needed for both potent antiviral activity and inhibition of cccDNA formation,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “While we are enthusiastic about these results and the antiviral activity shown in our Phase 1b study of our other next-generation core inhibitor, 3733, in HBV patients, we recognize that demonstrating the ability of next-generation core inhibitors to inhibit cccDNA formation in the clinic, which we view as a critical part of HBV cure, will require longer-duration Phase 2 studies. Because of this, we believe partnering our core inhibitor portfolio would enable additional opportunities for further clinical development for this compelling mechanism aimed at achieving a functional cure for HBV, including opening up other avenues for combination approaches.” “We are prioritizing our expanded virology pipeline because we believe these programs offer higher potential to have a near-term impact for patients and stockholders,” continued Mr. Okazaki. “Over the past three years, we have built a strategically diverse portfolio designed to address sig...